INS and type 1 diabetes mellitus: Better results came from a double‐blind, randomized, crossover trial in which T1D patients with weight excess (obese, 63%) were treated with Semaglutide up to 1 mg (or the maximum tolerated dose) and followed up to 12 weeks, comprising 2 months of titration in add‐on to a background insulin pump and 4 weeks of full‐dose Semaglutide plus an automated insulin delivery system to reduce biases.